ClinicalTrials.Veeva

Menu

Registration Study for Rare Type of Pulmonary Hypertension

N

National Center for Cardiovascular Diseases

Status

Enrolling

Conditions

Pulmonary Hypertension

Treatments

Other: laboratory biomarker analysis
Genetic: Genetic analysis

Study type

Observational

Funder types

Other

Identifiers

NCT03169010
RarePH135

Details and patient eligibility

About

The knowledge on the rare type of pulmonary hypertension which can not be explained by left heart disease, respiratory disease or congenital heart disease is very limited. Investigators aim to setup a national registration study for the rare type of pulmonary hypertension, to understand the natural history, survival, progression, genetic and environmental contributions to disease.

Full description

The main research contents of this registration study includes:

  1. Build a baseline database of the rare type of pulmonary hypertension. Collect general information, on-set symptoms and time, laboratory examination, imaging results, right heart catheterization and treatment information.
  2. Follow up recruited patients at regular intervals(6m~1y). Collect information on change in patients condition, laboratory test and treatment.
  3. Conduct genetic testing for gene mutation related or hereditary pulmonary hypertension. Link the clinical database to genetic database.
  4. Establish bio-bank for serum/plasma, urine, stool, tissues or cells.
  5. Establish prognostic study based on the clinical follow-up and genetic database.
  6. Draw diagnostic and treatment algorithm for the rare type of pulmonary hypertension.

Controls subjects: blood sample and medical data collected once.

Enrollment

2,000 estimated patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Participant is willing and able to give informed consent for participation in the study.
  • Patients diagnosed as idiopathic pulmonary artery hypertension, hereditary pulmonary artery hypertension, hereditary hemorrhagic telangiectasia associated pulmonary artery hypertension, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis associated pulmonary artery hypertension, cavernous transformation of portal vein associated pulmonary artery hypertension, special type of congenital heart disease associated pulmonary artery hypertension, chronic thromboembolism pulmonary hypertension.
  • All patients should have undergone right heart catheterization, diagnosed according to the guideline.

Exclusion criteria

The participant may not enter the study if ANY of the following apply:

  • Patients unwilling or unable to provide written consent for participation in the study.
  • Not suffering from the rare type of pulmonary artery hypertension;

Inclusion criteria-Controls

  • Participant is willing and able to give informed consent for participation in the study.
  • Self-reported to be healthy

Trial design

2,000 participants in 8 patient groups

Idiopathic Pulmonary Artery Hypertension
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
Hereditary PAH
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
Hereditary Hemorrhagic Telangiectasia
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
Pulmonary Veno-Occlusive Disease (PVOD)
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
Pulmonary Capillary Hemangiomatosis
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
Cavernous Transformation of Portal Vein
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
CTEPH
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis
Pulmonary Takaysu Arteritis
Description:
Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
Treatment:
Other: laboratory biomarker analysis
Genetic: Genetic analysis

Trial contacts and locations

1

Loading...

Central trial contact

Xi-Qi XU, MD. PhD.; Xin JIANG, MD. PhD.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems